keyword
MENU ▼
Read by QxMD icon Read
search

cetuximab head and neck cancers

keyword
https://www.readbyqxmd.com/read/27892728/a-phase-i-ii-study-of-nab-paclitaxel-cisplatin-and-cetuximab-with-concurrent-radiation-therapy-for-locally-advanced-squamous-cell-cancer-of-the-head-and-neck
#1
Stephen G Chun, Randall Hughes, Baran D Sumer, Larry L Myers, John M Truelson, Saad A Khan, Tsung-Wei Ma, Yang Xie, John S Yordy, Susan Cooley, Jean Wu, Hak Choy, Lucien A Nedzi
Nab-paclitaxel might impact efficacy of radiation for head and neck (H&N) cancer. Nab-paclitaxel, cisplatin, cetuximab, and radiation were evaluated in patients with locally advanced head and neck cancer in this phase I/II trial. Median follow-up was 24 months for 34 patients. The maximum tolerated dose of nab-paclitaxel was 20 mg/m(2) with 20 mg/m(2) cisplatin and 250 mg/m(2) cetuximab. The 2-year progression-free survival (PFS) was 60% (95% confidence interval (CI) 0.42, 0.78), local control 71% (95% CI 0...
November 28, 2016: Cancer Investigation
https://www.readbyqxmd.com/read/27880014/inhibition-of-epithelial-mesenchymal-transition-by-cetuximab-via-the-egfr-gep100-arf6-amap1-pathway-in-head-and-neck-cancer
#2
Yoshifumi Matsumoto, Hiroyuki Sakurai, Yasunao Kogashiwa, Toru Kimura, Yuma Matsumoto, Takashi Shionome, Masatake Asano, Koichiro Saito, Naoyuki Kohno
BACKGROUND: Despite improved survival by the addition of a monoclonal antibody against epidermal growth factor receptor (EGFR), cetuximab, to chemotherapy or radiotherapy for squamous cell carcinoma of the head and neck (SCCHN), cetuximab by itself is not a potent antiproliferative agent against SCCHN. We aimed to elucidate working mechanism of cetuximab in SCCHN. METHODS: The effect of cetuximab on the proliferation, migration, invasion, epithelial-mesenchymal transition, and signaling events downstream of the EGFR were investigated in 4 SCCHN cell lines...
November 23, 2016: Head & Neck
https://www.readbyqxmd.com/read/27849340/intra-arterial-cetuximab-for-the-treatment-of-recurrent-unresectable-head-and-neck-squamous-cell-carcinoma-%C3%A2
#3
Tristan Tham, Timothy G White, Shamik Chakraborty, Rohan R Lall, Rafael Ortiz, David J Langer, Deborah Shatzkes, Christopher G Filippi, Dennis Kraus, John A Boockvar, Peter D Costantino
IMPORTANCE: Management of recurrent head and neck squamous cell carcinoma is a common and challenging clinical problem in head and neck oncology. OBJECTIVE: Here we present the first reported case of super-selective intra-arterial (SSIA) microcatheter based local delivery of cetuximab for head and neck cancer. This technical report describes the techniques used to deliver the SSIA dose of cetuximab, as well as the patient outcome. DESIGN: This technical report is part of an ongoing Phase I Clinical Trial...
November 2016: Journal of Experimental Therapeutics & Oncology
https://www.readbyqxmd.com/read/27813277/comparison-between-weekly-cisplatin-enhanced-radiotherapy-and-cetuximab-enhanced-radiotherapy-in-locally-advanced-head-and-neck-cancer-first-retrospective-study-in-asian-population
#4
Sheh Rawat, Parveen Ahlawat, Anjali Kakria, Gaurav Kumar, Ranga Rao Rangaraju, Abhishek Puri, Manoj Pal, Deepika Chauhan, Bharti Devnani, Pranav Chadha
AIM: To present a direct comparison between chemotherapy-enhanced radiotherapy (CERT) and biotherapy-enhanced radiotherapy (BERT) in locally advanced head and neck cancer. METHODS: It is a retrospective analysis of 53 patients with locally advanced head and neck cancer treated from August 2006 to December 2008. For CERT, patients received weekly cisplatin (40 mg/m(2) ) and for BERT, a loading dose of 400 mg/m(2) of cetuximab given one week prior to radiotherapy followed by 250 mg/m(2) given weekly along with radiotherapy...
November 3, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27749515/cetuximab-pharmacokinetics-influences-overall-survival-in-head-and-neck-cancer-patients
#5
Yoann Pointreau, Nicolas Azzopardi, David Ternant, Gilles Calais, Gilles Paintaud
BACKGROUND: A retrospective study was conducted to analyze interindividual variability of cetuximab pharmacokinetics and its influence on survival (Progression Free Survival - PFS and overall survival - OS) in a cohort of head and neck squamous cell carcinoma (HNSCC). METHODS: Thirty-four patients received cetuximab as an infusion loading dose of 400 mg/m followed by weekly infusions of 250 mg/m. Twenty-one patients had locally advanced HNSCC (LAHNSCC) and thirteen had metastatic/recurrent HNSCC (MHNSCC)...
July 4, 2016: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/27741378/assessing-feasibility-compliance-and-toxicity-of-concomitant-chemo-radiotherapy-in-head-and-neck-cancers-in-the-northern-territory-initial-experience-and-challenges
#6
Ajay Gupta, Siddhartha Baxi, Christopher Hoyne
INTRODUCTION: Comprehensive oncology services have recently been introduced in the Northern Territory (NT) enabling delivery of concurrent chemo-radiotherapy (CCRT) in locally advanced head and neck squamous cell carcinoma (LAHNSC). The purpose of this study is to assess feasibility, compliance and toxicity of CCRT in remote Australia. METHODS: Chart review was conducted for all patients >18 years, with biopsy-proven LAHNSC, receiving curative intent CCRT between January 2010 and September 2012...
July 1, 2016: Journal of Medical Radiation Sciences
https://www.readbyqxmd.com/read/27734748/cost-analysis-of-cetuximab-erbitux-plus-radiotherapy-ert-versus-concomitant-cisplatin-plus-radiotherapy-crt-within-an-nhs-oncology-unit-single-institution-a-pilot-study
#7
Brammer Caroline, Yahya Sundus, Dawson Dawn, Glaister Carol, Merrick Susan
OBJECTIVE: The aim of this feasibility study is to define the resource effectiveness of cetuximab vs cisplatin given concomitantly with radiotherapy for squamous cell carcinoma within a National Health Service clinical oncology unit. METHODS: 20 patients with Stage 3 or 4 head and neck squamous cell cancers were randomized to receive either cetuximab with radiotherapy (ERT) or cisplatin with radiotherapy concurrent with external beam radiotherapy 70 Gy in 35 fractions on a 1 : 1 basis over a 12-month duration...
December 2016: British Journal of Radiology
https://www.readbyqxmd.com/read/27730326/radiotherapy-for-elderly-patients-and-cetuximab-a-monocentric-study
#8
Alexander T Falk, Christophe Hébert, Antoine Tran, Marie-Eve Chand, Axel Leysalle, Juliette Thariat, Olivier Dassonville, Gilles Poissonnet, Alexandre Bozec, Esma Saada, Fréderic Peyrade, Karen Benezery
Concomitant radiotherapy and cetuximab association has shown superiority to exclusive radiotherapy for head and neck cancers. Data on this association are scarce for the elderly population despite its rising incidence. A retrospective monocentric data collection was performed in the Antoine Lacassagne Cancer Center in France. Inclusion criteria were: age >70 years at time of diagnosis, histologically proven head and neck epidermoid carcinoma, treated with radiotherapy combined with cetuximab. Thirty-five patients were included between 2008 and 2012...
October 11, 2016: European Archives of Oto-rhino-laryngology
https://www.readbyqxmd.com/read/27727066/quality-of-life-and-performance-status-from-a-substudy-conducted-within-a-prospective-phase-3-randomized-trial-of-concurrent-accelerated-radiation-plus-cisplatin-with-or-without-cetuximab-for-locally-advanced-head-and-neck-carcinoma-nrg-oncology-radiation-therapy
#9
Minh Tam Truong, Qiang Zhang, David I Rosenthal, Marcie List, Rita Axelrod, Eric Sherman, Randal Weber, Phuc Felix Nguyen-Tân, Adel El-Naggar, André Konski, James Galvin, David Schwartz, Andy Trotti, Craig Silverman, Anurag Singh, Karen Godette, James A Bonner, Christopher U Jones, Adam S Garden, George Shenouda, Chance Matthiesen, Quynh-Thu Le, Deborah Bruner
PURPOSE: To analyze the quality of life (QOL) and performance status (PS) (secondary outcome) in patients with stage III to IV head and neck cancer (HNC) enrolled on a prospective randomized phase 3 trial comparing radiation-cisplatin without cetuximab (CIS) or with cetuximab (CET/CIS). The QOL hypothesis proposed a between-arm difference in Functional Assessment of Cancer Therapy-Head and Neck (FACT-HN) total score of ≥10% of the instrument range from baseline to 1 year. METHODS AND MATERIALS: Patients who gave consent to the QOL/PS study completed the FACT-HN, Performance Status Scale for HNC (PSS-HN), and EuroQol (EQ-5D) at baseline through to 5 years...
August 12, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27716204/insulin-growth-factor-1-like-receptor-igf-1r
#10
Gopal Iyer, James Price, Shay Bourgeois, Eric Armstrong, Shyhmin Huang, Paul M Harari
BACKGROUND: The epidermal growth factor receptor (EGFR) is frequently overexpressed in head and neck squamous cell carcinoma (HNSCC) and several other human cancers. Monoclonal antibodies, such as cetuximab that block EGFR signaling, have emerged as valuable molecular targeting agents in clinical cancer therapy. Prolonged exposure to cetuximab can result in cells acquiring resistance by a process that remains incompletely understood. METHODS: In this study, we analyzed the immediate early molecular response of cetuximab on physical interactions between EGFR and Insulin growth factor 1 like receptor (IGF-1R) in head and neck cancer cells that are resistant to cetuximab...
October 6, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27693630/acetyl-coa-carboxylase-rewires-cancer-metabolism-to-allow-cancer-cells-to-survive-inhibition-of-the-warburg-effect-by-cetuximab
#11
Jingtao Luo, Yun Hong, Yang Lu, Songbo Qiu, Bharat K R Chaganty, Lun Zhang, Xudong Wang, Qiang Li, Zhen Fan
Cetuximab inhibits HIF-1-regulated glycolysis in cancer cells, thereby reversing the Warburg effect and leading to inhibition of cancer cell metabolism. AMP-activated protein kinase (AMPK) is activated after cetuximab treatment, and a sustained AMPK activity is a mechanism contributing to cetuximab resistance. Here, we investigated how acetyl-CoA carboxylase (ACC), a downstream target of AMPK, rewires cancer metabolism in response to cetuximab treatment. We found that introduction of experimental ACC mutants lacking the AMPK phosphorylation sites (ACC1_S79A and ACC2_S212A) into head and neck squamous cell carcinoma (HNSCC) cells protected HNSCC cells from cetuximab-induced growth inhibition...
January 1, 2017: Cancer Letters
https://www.readbyqxmd.com/read/27685907/cbl-b-regulates-the-sensitivity-of-cetuximab-through-ubiquitin-proteasome-system-in-human-gastric-cancer-cells
#12
Ping Yu, Yibo Fan, Xiujuan Qu, Jingdong Zhang, Na Song, Jing Liu, Yunpeng Liu
PURPOSE: Cetuximab is a monoclonal antibody against epidermal growth factor receptor (EGFR) and is approved for clinical use in combination with chemotherapy in patients affected by colorectal cancer (CRC), non small cell lung cancer (NSCLC), and head and neck cancer. Compared with these cancers, gastric cancer is relatively resistant to cetuximab and its regulatory mechanism is still unclear. METHODS: In this study, we assessed whether the ubiquitin- proteasome pathway is involved in regulating cetuximab-induced cells apoptosis in MGC803 and BGC823 gastric cancer cell lines...
July 2016: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/27683640/incidence-and-risk-factors-of-hypomagnesemia-in-head-and-neck-cancer-patients-treated-with-cetuximab
#13
Tomohiro Enokida, Shinya Suzuki, Tetsuro Wakasugi, Tomoko Yamazaki, Susumu Okano, Makoto Tahara
BACKGROUND: Hypomagnesemia is a common adverse event during cetuximab (Cmab) treatment. However, few reports have investigated the incidence and risk factors of hypomagnesemia in head and neck cancer patients treated with Cmab. METHODS: We retrospectively reviewed 131 head and neck cancer patients who received Cmab-containing therapy. Main eligibility criteria were ≥3 Cmab administrations, no prior EGFR-directed therapy, and no prophylactic Mg supplementation...
2016: Frontiers in Oncology
https://www.readbyqxmd.com/read/27681990/extrapolation-of-survival-curves-from-cancer-trials-using-external-information
#14
Patricia Guyot, A E Ades, Matthew Beasley, Béranger Lueza, Jean-Pierre Pignon, Nicky J Welton
BACKGROUND: Estimates of life expectancy are a key input to cost-effectiveness analysis (CEA) models for cancer treatments. Due to the limited follow-up in Randomized Controlled Trials (RCTs), parametric models are frequently used to extrapolate survival outcomes beyond the RCT period. However, different parametric models that fit the RCT data equally well may generate highly divergent predictions of treatment-related gain in life expectancy. Here, we investigate the use of information external to the RCT data to inform model choice and estimation of life expectancy...
September 28, 2016: Medical Decision Making: An International Journal of the Society for Medical Decision Making
https://www.readbyqxmd.com/read/27662818/utility-of-serum-anti-cetuximab-ige-levels-to-identify-patients-at-a-high-risk-of-severe-hypersensitivity-reaction-to-cetuximab
#15
B Dupont, D Mariotte, A E Dugué, B Clarisse, J-M Grellard, E Babin, B Chauffert, S Dakpé, C Moldovan, K Bouhier-Leporrier, J-M Reimund, F Di Fiore, S Zanetta, A Mailliez, P Do, A Peytier, M-P Galais, C Florescu, R Schott, B Le Mauff, R Gervais
AIM: Cetuximab is an anti-EGFR antibody used for the treatment of metastatic colorectal cancer and head and neck cancer. Hypersensitivity reactions (HSR) are associated with cetuximab use. The aim of the study was to evaluate the utility of anti-cetuximab IgE detection in order to identify patients at risk of HSR to cetuximab. METHODS: We included patients ready to receive a first cetuximab infusion in a prospective cohort carried out at 9 French centers. Pre-treatment anti-cetuximab IgE levels were measured...
September 24, 2016: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27643613/spheroid-culture-of-head-and-neck-cancer-cells-reveals-an-important-role-of-egfr-signalling-in-anchorage-independent-survival
#16
Diana Braunholz, Mohammad Saki, Franziska Niehr, Merve Öztürk, Berta Borràs Puértolas, Robert Konschak, Volker Budach, Ingeborg Tinhofer
In solid tumours millions of cells are shed into the blood circulation each day. Only a subset of these circulating tumour cells (CTCs) survive, many of them presumable because of their potential to form multi-cellular clusters also named spheroids. Tumour cells within these spheroids are protected from anoikis, which allows them to metastasize to distant organs or re-seed at the primary site. We used spheroid cultures of head and neck squamous cell carcinoma (HNSCC) cell lines as a model for such CTC clusters for determining the role of the epidermal growth factor receptor (EGFR) in cluster formation ability and cell survival after detachment from the extra-cellular matrix...
2016: PloS One
https://www.readbyqxmd.com/read/27635865/artificial-nutrition-dependence-after-cetuximab-versus-cisplatin-combined-with-radiotherapy-for-advanced-head-and-neck-cancer-a-propensity-score-matched-analysis
#17
Miho Ishimaru, Sachiko Ono, Sayaka Suzuki, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga
BACKGROUND: The purpose of this study was to compare the effect of cetuximab-based radiotherapy (RT) with cisplatin-based concomitant chemoradiotherapy (CCRT) on artificial nutrition dependence in locoregional advanced head and neck cancer. METHODS: We identified patients treated with cetuximab-based RT or CCRT between 2012 and 2014 in a Japanese national database, and used propensity score-matched analyses to evaluate artificial nutrition dependence for 30 days after starting chemotherapy and at hospital discharge...
September 16, 2016: Head & Neck
https://www.readbyqxmd.com/read/27631463/cetuximab-pharmacokinetics-influences-overall-survival-in-patients-with-head-and-neck-cancer
#18
Yoann Pointreau, Nicolas Azzopardi, David Ternant, Gilles Calais, Gilles Paintaud
BACKGROUND: A retrospective study was conducted to analyze interindividual variability of cetuximab pharmacokinetics and its influence on survival (progression-free survival and overall survival [OS]) in a cohort of head and neck squamous cell carcinoma (HNSCC). METHODS: Thirty-four patients received cetuximab as an infusion loading dose of 400 mg/m followed by weekly infusions of 250 mg/m. Twenty-one patients had locally advanced HNSCC, and 13 had metastatic/recurrent HNSCC...
October 2016: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/27623508/immunotherapy-in-head-and-neck-cancer-harnessing-profit-on-a-system-disruption
#19
REVIEW
Chloé Rancoule, Alexis Vallard, Sophie Espenel, Jean-Baptiste Guy, Yaoxiong Xia, Anis El Meddeb Hamrouni, Claire Rodriguez-Lafrasse, Cyrus Chargari, Eric Deutsch, Nicolas Magné
Immune system deregulation and evasion play a key role in cancers' evolution and progression, including squamous cell carcinoma of the head and neck (SCCHN). Development of basic research proposed a whole new vision of cancer treatment, based on a strong biological rational, and targeting intrinsic deregulations. Immunotherapies provide an encouraging strategy for patients' improved outcomes. Immune-based therapies could act on cancer growth and/or development throughout many pathways. If cetuximab is for now the only monoclonal antibody approved for SCCHN management, other strategies, e...
November 2016: Oral Oncology
https://www.readbyqxmd.com/read/27601039/-relevance-of-hpv-infections-in-head-and-neck-cancers-highlights-of-the-2016-asco-annual-meeting
#20
M Hoffmann
The papers on human papillomavirus (HPV) infections in head and neck carcinomas presented during the ASCO Meeting in 2016 investigated factors influencing the survival of patients with known HPV status. Interestingly, women suffering from oropharyngeal carcinomas show better survival than men do. This is believed to be the consequence of differences in the immune system of male and female patients. Another interesting finding is that the HPV status in cases of locoregional recurrence of oropharyngeal carcinomas represents a positive predictive marker for patient survival...
October 2016: HNO
keyword
keyword
54952
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"